| 臺大學術典藏 |
2018-09-10T18:04:10Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Yao, Z.-H. and Liao, W.-Y. and Ho, C.-C. and Chen, K.-Y. and Shih, J.-Y. and Chen, J.-S. and Lin, Z.-Z. and Lin, C.-C. and Yang, J.C.H. and Yu, C.-J.; Chong-Jen Yu; WEI-YU LIAO; JIN-YUAN SHIH; JIN-SHING CHEN |
| 臺大學術典藏 |
2020-08-12T02:50:42Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Lin C.-C.; Yang J.C.H.; Yu C.-J.; Lin Z.-Z.; Chen J.-S.; Yao Z.-H.; Liao W.-Y.; CHAO-CHI HO; Chen K.-Y.; Shih J.-Y.; Yao Z.-H.;Liao W.-Y.;Chao-Chi Ho;Chen K.-Y.;Shih J.-Y.;Chen J.-S.;Lin Z.-Z.;Lin C.-C.;Yang J.C.H.;Yu C.-J. |
| 國家衛生研究院 |
2023-02-05 |
Real-world data validation of NAPOLI-1 nomogram for the prediction of overall survival in metastatic pancreatic cancer
|
Su, YY;Chiang, NJ;Yang, YH;Yen, CJ;Bai, LY;Chiu, CF;Chuang, SC;Yang, SH;Chou, WC;Chen, JS;Chiu, TJ;Chen, YY;Chan, DC;Peng, CM;Chiu, SC;Li, CP;Shan, YS;Chen, LT |
| 國立成功大學 |
2023-02 |
Real-World Data Validation of NAPOLI-1 Nomogram for the Prediction of Overall Survival in Metastatic Pancreatic Cancer
|
Su;Yung-Yeh;Chiang;Nai-Jung;Yang;Yi-Hsin;Yen;Chia-Jui;Bai;Li-Yuan;Chiu;Chang-Fang;Chuang;Shih-Chang;Yang;Shih-Hung;Chou;Wen-Chi;Chen;Jen-Shi;Chiu;Tai-Jan;Chen;Yen-Yang;Chan;De-Chuan;Peng;Cheng-Ming;Chiu;Sz-Chi;Li;Chung-Pin;Shan;Yan-Shen;Chen;Li-Tzong |
| 國立成功大學 |
2024-06 |
Real-world effectiveness and safety of 8-week glecaprevir/pibrentasvir for treatment-naive patients from Taiwan nationwide HCV registry
|
Huang;Chung-Feng;Chang;Te-Sheng;Kuo;Hsing-Tao;Huang;Chien-Wei;Mo;Lien-Ray;Tai;Chi-Ming;Tseng;Kuo-Chih;Bair;Ming-Jong;Wang;Sih-Ren;Lo;Ching-Chu;Chong;Lee-Won;Cheng;Pin-Nan;Yeh;Ming-Lun;Peng;Cheng-Yuan;Cheng;Chien-Yu;Huang;Jee-Fu;Lin;Chih-Lang;Yang;Chi-Chieh;Hsieh;Tsai-Yuan;Lee;Tzong-Hsi;Lee;Pei-Lun;Wu;Wen-Chih;Lin;Chih-Lin;Su;Wei-Wen;Yang;Sheng-Shun;Wang;Chia-Chi;Hu;Jui-Ting;Chen;Chun-Ting;Huang;Yi-Hsiang;Chang;Chun-Chao;Huang;Chia-Sheng;Chen;Guei-Ying;Kao;Chien-Neng;Liu;Chun-Jen;Lee;Mei-Hsuan;Tsai;Pei-Chien;Dai;Chia-Yen;Kao;Jia-Horng;Lin;Han-Chieh;Chuang;Wan-Long;Hung;Chao-Hung;Chen;Chi-Yi;Yu;Ming-Lung |
| 臺大學術典藏 |
2019 |
Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C
|
Hsu S.-J.; Chiu M.-C.; Fang Y.-J.; Yang T.-H.; Yu J.-J.; CHIEH-CHANG CHEN; Kuo C.-C.; Lee J.-Y.; Chen C.-H.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-02-22T05:34:12Z |
Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C
|
Hsu S.-J.; Chiu M.-C.; Fang Y.-J.; Yang T.-H.; Yu J.-J.; Chen C.-C.; Kuo C.-C.; Lee J.-Y.; CHIEN-HUNG CHEN; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-02-14T06:28:47Z |
Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C
|
Hsu S.-J.; Chiu M.-C.; YU-JEN FANG; Yang T.-H.; Yu J.-J.; Chen C.-C.; Kuo C.-C.; Lee J.-Y.; Chen C.-H.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-02-18T08:25:58Z |
Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C
|
Hsu S.-J.; Chiu M.-C.; Fang Y.-J.; Yang T.-H.; Yu J.-J.; CHIEH-CHANG CHEN; Kuo C.-C.; Lee J.-Y.; Chen C.-H.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-02-23T02:12:23Z |
Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C
|
Hsu S.-J.; Chiu M.-C.; Fang Y.-J.; Yang T.-H.; Yu J.-J.; Chen C.-C.; Kuo C.-C.; Lee J.-Y.; CHIEN-HUNG CHEN; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-09-04T05:16:49Z |
Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C
|
Hsu S.-J.; Chiu M.-C.; Fang Y.-J.; Yang T.-H.; Yu J.-J.; Chen C.-C.; Kuo C.-C.; Lee J.-Y.; Chen C.-H.; Chen D.-S.; JIA-HORNG KAO |
| 國立成功大學 |
2020-03-01 |
Real-world effectiveness and safety of ledipasvir/sofosbuvir for genotype 6 chronic hepatitis C patients in Taiwan
|
鄭斌男; 陳志州;李佩倫;邱宏志;董宏達;邱彥程 |
| 國立成功大學 |
2020-03 |
Real-world effectiveness and safety of ledipasvir/sofosbuvir for genotype 6 chronic hepatitis C patients in Taiwan
|
Chen;Jyh-Jou;Lee;Pei-Lun;Chiu;Hung-Chih;Tung;Hung-Da;Chiu;Yen-Cheng;Cheng;Pin-Nan |
| 臺大學術典藏 |
2021-05-24T07:20:28Z |
Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan
|
CHEN-HUA LIU; Liu C.-J.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-06-25T08:10:15Z |
Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan
|
Liu C.-H.; Liu C.-J.; Su T.-H.; Yang H.-C.; CHUN-MING HONG; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-07-03T03:33:40Z |
Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan
|
Liu C.-H.; Liu C.-J.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; PEI-JER CHEN; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-07-12T02:44:33Z |
Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan
|
Liu C.-H; | Liu C.-J; | Su T.-H; | HUNG-CHIH YANG; | Hong C.-M; | Tseng T.-C; | Chen P.-J; | Chen D.-S; | Kao J.-H. |
| 臺大學術典藏 |
2021-09-04T05:17:09Z |
Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan
|
Liu C.-H.; Liu C.-J.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2022-01-24T09:31:21Z |
Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan
|
Liu C.-H.; CHUN-JEN LIU; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T01:43:23Z |
Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan
|
Liu C.-H.; Liu C.-J.; TUNG-HUNG SU; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-03-09T01:43:20Z |
Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan
|
Liu C.-H.; Liu C.-J.; TUNG-HUNG SU; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-05-24T07:20:25Z |
Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan
|
CHEN-HUA LIU; Liu C.-J.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-06-25T08:10:13Z |
Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan
|
Liu C.-H.; Liu C.-J.; Su T.-H.; Yang H.-C.; CHUN-MING HONG; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2021-07-12T02:44:29Z |
Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan
|
Liu C.-H; | Liu C.-J; | Su T.-H; | HUNG-CHIH YANG; | Hong C.-M; | Tseng T.-C; | Chen P.-J; | Chen D.-S; | Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:17Z |
Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan
|
Liu C.-H.; CHUN-JEN LIU; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
